218
Views
2
CrossRef citations to date
0
Altmetric
Epidemiology

A Brazilian multicentre study on the clinical and epidemiological profiles of 1116 patients with amyotrophic lateral sclerosis and its phenotypic variants

ORCID Icon, , , &
Pages 353-362 | Received 26 Aug 2021, Accepted 07 Nov 2021, Published online: 25 Nov 2021

References

  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
  • Couratier P, Corcia P, Lautrette G, Nicol M, Preux P-M, Marin B, et al. Epidemiology of amyotrophic lateral sclerosis: a review of literature. Rev Neurol (Paris). 2016;172:37–45.
  • Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
  • Rutter-Locher Z, Turner MR, Leigh PN, Al-Chalabi A. Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:600–4.
  • Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182–94.
  • Zou Z-Y, Zhou Z-R, Che C-H, Liu C-Y, He R-L, Huang H-P, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540–9.
  • Nunes Gonçalves JP, Leoni TB, Martins MP, Peluzzo TM, Dourado MET, Saute JAM, et al. Genetic epidemiology of familial ALS in Brazil. Neurobiol Aging. 2021;102:227.e1–e4.
  • Souza A. M d, Resende SS, Sousa T. N d, Brito C. F A d. A systematic scoping review of the genetic ancestry of the Brazilian population. Genet Mol Biol. 2019;42:495–508.
  • Matos S. E d, Conde MTRP, Fávero FM, Taniguchi M, Quadros AAJ, Fontes SV, et al. Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006. Arq Neuropsiquiatr. 2011;69:861–6.
  • Favero FM, Voos MC, de Abreu LC, de Castro I, Caromano FA, Juviniano Quadros AA, et al. Epidemiological and clinical factors impact on survival in ALS/MND: a cohort study. Int Arch Med. 2015;8:1–8.
  • Visser AE, Rooney JPK, D’Ovidio F, Westeneng H-J, Vermeulen RCH, Beghi E, et al. Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:797–803.
  • Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
  • Prado L. d G R, Bicalho ICS, Vidigal-Lopes M, Ferreira CJA, Mageste Barbosa LS, Gomez RS, et al. Amyotrophic lateral sclerosis in Brazil: case series and review of the Brazilian literature. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:282–8.
  • (DATASUS) DdIdS. Sistema de Informação de Mortalidade (SIM). http://sim.saude.gov.br/default.asp (accessed 07/01/2021 2021).
  • United Nations. UNDP Brazil. https://www.br.undp.org/content/brazil/pt/home.html (accessed 2021 Apr 15.).
  • Curi RLC, Gasalla MA. Social vulnerability and human development of Brazilian coastal populations. Front Ecol Evol. 2021; 9:9.
  • Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
  • Brooks BR. El Escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124:96–107.
  • Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557–63.
  • Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian national motor neuron disease observational cohort. BMJ Open. 2016;6:e012054.
  • Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J, et al. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. Amyotroph Lateral Scler. 2010;11:379–82.
  • Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ, et al. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2016;87:611–9.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.
  • Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291–2.
  • Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330:585–91.
  • Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135:2883–91.
  • Sabatelli M, Zollino M, Luigetti M, Grande AD, Lattante S, Marangi G, et al. Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow-up of upper motor neuron-dominant ALS. Amyotroph Lateral Scler. 2011;12:278–82.
  • Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157–9.
  • Logroscino G, Traynor BJ, Hardiman O, Chio' A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11.
  • Beghi E, Balzarini C, Bogliun G, Logroscino G, Manfredi L, Mazzini L, et al. Reliability of the El Escorial diagnostic criteria for amyotrophic lateral sclerosis. Neuroepidemiology 2002;21:265–70.
  • Bucheli M, Andino A, Montalvo M, Cruz J, Atassi N, Berry J, et al. Amyotrophic lateral sclerosis: analysis of ALS cases in a predominantly admixed population of Ecuador. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:106–13.
  • Luna J, Diagana M, Ait Aissa L, Tazir M, Ali Pacha L, Kacem I, et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. J Neurol Neurosurg Psychiatry. 2019;90:20–9.
  • Marin B, Logroscino G, Boumédiene F, Labrunie A, Couratier P, Babron M-C, et al. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur J Epidemiol. 2016;31:229–45.
  • Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–22.
  • Collaborators GBDMND. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:1083–97.
  • Rooney J, Vajda A, Heverin M, Elamin M, Crampsie A, McLaughlin R, et al. Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology 2015;84:1537–44.
  • Logroscino G, Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology 2019;52:93–103.
  • Nishimura AL, Mitne-Neto M, Silva HCA, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822–31.
  • Parton MJ, Broom W, Andersen PM, Al-Chalabi A, Nigel Leigh P, Powell JF, et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype. Hum Mutat. 2002;20:473.
  • Chiò A, Borghero G, Pugliatti M, Ticca A, Calvo A, Moglia C, et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch Neurol. 2011;68:594–8.
  • Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, et al. Differentiating lower motor neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88:474–83.
  • Fávero FM, Voos MC, Castro I. d, Caromano FA, Oliveira ASB. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS. Arq Neuropsiquiatr. 2017;75:515–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.